Kidney Stone Disease In ADPKD

ADPKD 中的肾结石病

基本信息

  • 批准号:
    10651868
  • 负责人:
  • 金额:
    $ 45.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-22 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT/SUMMARY Autosomal dominant polycystic kidney (ADPKD) affects an estimated 600,000 individuals in the US and accounts for 5% of patients with end-stage kidney disease (ESKD). At the current time there is only one approved therapy available for patients diagnosed with rapidly progressing disease. This underlines the need for identification of additional measures to slow kidney disease progression in ADPKD patients. Kidney stone disease is highly prevalent, increasingly common, and associated with considerable comorbidity among patients affected with ADPKD. In this proposal, we build on our preliminary data which demonstrates that patients with ADPKD and kidney stone disease have a more rapid loss of kidney function compared to ADPKD patients without kidney stone disease. We will leverage an interdisciplinary team that is uniquely poised to define kidney stone disease in ADPKD by combining expertise in large data analytics and high-dimensional microbiome and metabolomic data. The overall goal of this application is to demonstrate that kidney stone disease in patients with ADPKD represents a significant risk factor for faster kidney disease progression and that antibiotic exposure increases stone risk in this population. A secondary goal is to determine how dysbiosis of the gut microbiome contributes to kidney stone disease. We hypothesize that kidney stone disease contributes to more rapid decline in kidney function in ADPKD through worsening inflammation and that antibiotics contribute to kidney stone disease by perturbing the gut-PKD axis through alterations of the gut microbiome. We test this hypothesis in 3 specific aims. In aim 1, we seek to describe the distribution and composition of kidney stones by sex and age and to determine the link between kidney stone disease and decline in kidney function independent of markers of inflammation and other known risk factors for kidney disease progression. In Aim 2 we investigate the link between antibiotic exposure and kidney stone disease while in Aim 3 we will define the link between oral antibiotic exposure and change in urinary kidney stone risk factors resultant from changes in the microbiome. We will leverage the Intermountain Healthcare System database with medical and pharmacy coverage, and clinical data including stone analysis and the longitudinal data and samples from the NIDDK sponsored HALT-PKD clinical trials. These resources will provide access to 1,823 patients with ADPKD including 296 with kidney stones. We will recruit 100 patients with ADPKD with or without antibiotic exposure to facilitate microbiome and stone risk analysis in aim 3. A barrier to developing new therapies for stone prevention is a lack of understanding of how perturbations of the gut microbiome and downstream metabolite changes in the intestinal and urinary tracts contributes to kidney stone disease. Understanding the gut-PKD axis from the proposed studies will introduce a new paradigm for kidney stone prevention in ADPKD and will provide key insights into novel therapeutic targets for kidney stone disease in ADPKD.
摘要/总结 常染色体显性多囊肾 (ADPKD) 影响美国约 600,000 人 占终末期肾病(ESKD)患者的 5%。目前只有一个 批准的治疗可用于诊断患有快速进展性疾病的患者。这强调了需要 确定减缓 ADPKD 患者肾脏疾病进展的其他措施。肾结石 该疾病非常普遍、日益常见,并且与人群中相当多的合并症相关 患有 ADPKD 的患者。在本提案中,我们以初步数据为基础,这些数据表明 与 ADPKD 相比,ADPKD 合并肾结石患者的肾功能丧失速度更快 无肾结石疾病的患者。我们将利用一支具有独特优势的跨学科团队 通过结合大数据分析和高维专业知识来定义 ADPKD 中的肾结石疾病 微生物组和代谢组数据。该应用程序的总体目标是证明肾结石 ADPKD 患者的疾病是肾脏疾病进展加快的一个重要危险因素, 接触抗生素会增加该人群的结石风险。第二个目标是确定生态失调如何 肠道微生物组的变化会导致肾结石疾病。我们推测肾结石病 通过恶化炎症导致 ADPKD 肾功能更快下降 抗生素通过改变肠道来扰乱肠道-PKD 轴,从而导致肾结石疾病 微生物组。我们通过 3 个具体目标来检验这一假设。在目标 1 中,我们试图描述分布和 按性别和年龄划分的肾结石组成,并确定肾结石疾病与肾结石之间的联系 肾功能下降与炎症标志物和其他已知的肾脏危险因素无关 疾病进展。在目标 2 中,我们调查抗生素暴露与肾结石疾病之间的联系 而在目标 3 中,我们将定义口服抗生素暴露与尿路肾结石风险变化之间的联系 微生物组变化引起的因素。我们将利用山间医疗保健系统 涵盖医疗和药房的数据库以及包括结石分析和纵向分析在内的临床数据 来自 NIDDK 赞助的 HALT-PKD 临床试验的数据和样本。这些资源将提供对 1,823 名 ADPKD 患者,其中 296 名患有肾结石。我们将招募 100 名 ADPKD 患者,其中患有或 无需接触抗生素即可促进目标 3 中的微生物组和结石风险分析。发展的障碍 预防结石的新疗法缺乏对肠道微生物群的扰动和 肠道和泌尿道下游代谢物的变化导致肾结石疾病。 从拟议的研究中了解肠道-PKD 轴将为肾结石引入新的范例 ADPKD 的预防,并将为肾结石疾病的新治疗靶点提供重要见解 ADPKD。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michel Benjamin Chonchol其他文献

Michel Benjamin Chonchol的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michel Benjamin Chonchol', 18)}}的其他基金

Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
  • 批准号:
    10464393
  • 财政年份:
    2022
  • 资助金额:
    $ 45.32万
  • 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
  • 批准号:
    10534531
  • 财政年份:
    2022
  • 资助金额:
    $ 45.32万
  • 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
  • 批准号:
    10684097
  • 财政年份:
    2022
  • 资助金额:
    $ 45.32万
  • 项目类别:
Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
  • 批准号:
    10626828
  • 财政年份:
    2022
  • 资助金额:
    $ 45.32万
  • 项目类别:
Kidney Stone Disease In ADPKD
ADPKD 中的肾结石病
  • 批准号:
    10387268
  • 财政年份:
    2021
  • 资助金额:
    $ 45.32万
  • 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
  • 批准号:
    10669712
  • 财政年份:
    2021
  • 资助金额:
    $ 45.32万
  • 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
  • 批准号:
    10313126
  • 财政年份:
    2021
  • 资助金额:
    $ 45.32万
  • 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
  • 批准号:
    10640074
  • 财政年份:
    2019
  • 资助金额:
    $ 45.32万
  • 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
  • 批准号:
    10400032
  • 财政年份:
    2019
  • 资助金额:
    $ 45.32万
  • 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
  • 批准号:
    9762288
  • 财政年份:
    2019
  • 资助金额:
    $ 45.32万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 45.32万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 45.32万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 45.32万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 45.32万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 45.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 45.32万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 45.32万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 45.32万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 45.32万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 45.32万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了